Catalyst Pharmaceuticals Inc. Common Stock (CPRX)

FairStock Score: 70/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-style analyst, I look first for a business that earns real money and does not need much debt. Catalyst Pharmaceuticals, at $31.49 on 2026-07-21, has a $3.3 billion market cap. It is a commercial-stage rare-disease biopharma with only 182 employees, selling Firdapse and Fycompa in the U.S. In the latest reported quarter, fiscal Q1 2026, it produced $149.4 million of revenue and $63.7 million of net income, a 42.66% net margin. That is a genuinely profitable niche business. The balance sheet is pristine: D/E is 0.00, and FairStock's calculations show ROE of 24.50%, ROCE of 16.27%, trailing free cash flow of $208.1 million, and a FairStock FCF yield of 6.4%. FairStock's Piotroski F-Score of 7/9 and Altman Z-Score of 16.30 support financial strength. The moat is hard to judge: the data show only two named products and no long filed history.

In plain English: Catalyst Pharmaceuticals is a commercial-stage biopharma that sells medicines for rare diseases in the U.S., including Firdapse for LEMS and Fycompa for seizures. The business looks financially strong: it earns good profits, has no debt, and generates cash. At the 2026-07-21 close of $31.49, the price looks full versus its accounting value, though not wildly expensive relative to current earnings.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-07-21 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer